Last reviewed · How we verify
Yohimbin (YOHIMBINE)
Yohimbine works by blocking the alpha-2A adrenergic receptor, which increases the release of norepinephrine and epinephrine, leading to increased alertness and energy.
Yohimbine, also known as YOHIMBINE, is a small molecule drug that targets the alpha-2A adrenergic receptor. It is classified as a yohimbine drug and its mechanism of action is not FDA approved for any indications. Yohimbine has a half-life of 1.5 hours and bioavailability of 33%. The commercial status of Yohimbine is unknown, and it is not approved for any specific indications. As a result, its use is largely off-label and requires careful consideration of its potential risks and benefits.
At a glance
| Generic name | YOHIMBINE |
|---|---|
| Drug class | yohimbine |
| Target | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Mechanism of action
Imagine your brain has a 'brake' that helps you relax and calm down. Yohimbine is like a key that unlocks this brake, allowing your brain to send more signals to your body to be more alert and active. This can be helpful for people who need a boost of energy or focus, but it can also have negative effects if not used carefully.
Approved indications
Common side effects
- Hypertensive emergency
- Haemorrhage intracranial
Key clinical trials
- Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions (NA)
- Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder (PHASE2)
- PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention (NA)
- Cannabinoids and Biological Reactivity to Stress (EARLY_PHASE1)
- [11C]Yohimbine PET Study of alpha2-AR (PHASE1)
- Opioidergic and Noradrenergic Systems in Central Parkisonian Pain (NA)
- Mifepristone for the Prevention of Relapses of Alcohol Drinking (PHASE1,PHASE2)
- Role Of Sensitivity to neuroEndocrine Systems in Social Decisions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yohimbin CI brief — competitive landscape report
- Yohimbin updates RSS · CI watch RSS